Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Gastroenterology. Author manuscript; available in PMC 2011 January 1.
Published in final edited form as:
PMCID: PMC2813361

The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling


Background & Aims

Gucy2c is the intestinal cell receptor for the paracrine hormones guanylin and uroguanylin that converts GTP to cyclic (c)GMP. It functions as a tumor suppressor; its loss disrupts intestinal homeostasis and promotes tumorigenesis. We investigated the effects of Gucy2c loss on intestinal cell proliferation, metabolism, signaling, and tumorigenesis in mice.


Intestinal cell proliferation and metabolism were examined in Gucy2c−/− and wild-type mice and human colon cancer cells by microscopy, immunoblot, and functional analyses. AKT regulation and signaling were examined and the role of AKT in Gucy2c-dependent tumorigenesis was defined in Gucy2c−/−Akt1−/− mice. Microarray analyses compared gene expression profiles of intestine of Gucy2c−/− and wild-type mice.


The size and number of intestinal crypts increased in Gucy2c−/− mice; the associated epithelial cells exhibited accelerated proliferation, increased glycolysis, and reduced oxidative phosphorylation, which was reversed by oral administration of cGMP. Conversely, activating GUCY2C in human colon cancer cells delayed cell cycle progression (inhibiting DNA synthesis and colony formation), reduced glycolysis, and increased mitochondrial ATP production. AKT signaling pathways were activated in intestines of Gucy2c−/− mice, associated with increased AKT phosphorylation. Disruption of AKT activity, pharmacologically or genetically, reduced DNA synthesis, proliferation, and glycolysis and increased mitochondrial biogenesis. Intestinal tumorigenesis increased following administration of azoxymethane to Gucy2c−/− mice, compared with wild-type mice, but was eliminated in Gucy2c−/−Akt1−/− mice.


Gucy2c is a tumor suppressor that controls proliferation and survival of intestinal epithelial cells by inactivating AKT signaling. This receptor and its ligands, which are paracrine hormones, might be novel candidates for anti-colorectal cancer therapy.


Disruption of developmental processes maintaining cellular homeostasis, including proliferation and metabolism, conveys an evolutionary advantage to cancer cells.14 Indeed, dysregulation of cell cycle progression and differentiation through targeted inactivation of p21 promotes APC mutation-dependent tumor formation by increasing proliferation and decreasing differentiation in intestine.5 Further, crypt hyperplasia, associated with disrupted differentiation, promotes intestinal tumorigenesis in mice with increased IGF2 expression6. Moreover, metabolic remodeling permits tumor cells to undergo energy-independent autonomous replication through intermediate metabolism, confers survival advantages under hypoxic conditions, and promotes further accumulation of mutations.7

GUCY2C is an intestine-specific receptor that catalyzes the conversion of guanosine-5'-triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) upon activation by the endogenous paracrine hormones guanylin and uroguanylin or the exogenous ligands, the diarrheagenic bacterial heat-stable enterotoxins (STs).813 Guanylin and uroguanylin exhibit a pattern of expression along the crypt-villus axis that is associated with the transition from proliferation to differentiation, absent in the crypt but present in the differentiated compartment.14 Additionally, these paracrine hormones are among the most commonly lost gene products in colorectal cancer, and their loss occurs early along the continuum of transformation.1517 Further, elimination of GUCY2C signaling disrupts intestinal homeostasis and tumor susceptibility.18, 19 In order to define the functional relevance of GUCY2C to mechanisms underlying epithelial homeostasis and intestinal tumorigenesis, we performed analyses to identify signaling targets of GUCY2C in processes supporting transformation.


For further details, please see Supplemental Experimental Procedures.

Animal models

Gucy2c−/− and Akt−/− C57BL/6 mice were bred, maintained, genotyped, and functionally characterized as described in accordance with the Thomas Jefferson University Animal Care and Use guidelines.19 Tumors were induced by azoxymethane, enumerated, and quantified as described (see supplemental procedures).19

Cell culture, siRNA transfection, and adenovirus infection

MC38 murine colon cancer cells were provided by J. Schlom (NCI, MD). A truncated mouse Gucy2c1-461 construct (Gucy2c-TM) containing extracellular ligand-binding and transmembrane domains, was generated as described.20 In some experiments, cells were transfected with targeted or control siRNA (25 nM; Millipore) by Lipofectamine® RNAiMAX (Invitrogen). Adenovirus-expressing AKT1 and myr-AKT were provided by T. Chan (Thomas Jefferson University, PA). Adenovirus-expressing siAKT1 and GFP were from Millipore.

Human Tissue

Human tissues were obtained from patients undergoing surgery under a protocol approved by the IRB (control no. 01.0823).


The anti-OxPhos complex IV subunit I antibody (Invitrogen) was used to stain mitochondria. The nuclear co-expression of pRb and cyclin D1 was quantified using anti-phospho-Rb and anti-cyclin D1 (Santa Cruz Biotechnology). Anti-hexokinase II antibody (Santa Cruz Biotechnology) was used to detect metabolic markers. DNA oxidized by ROS was quantified using anti-8-oxo-dG antibody (Trevigen). Stained tissues were quantified in 5 to 15 crypt-villus units/intestinal segment/mouse.

Immunoblot analyses

Protein was extracted from cells and tissues in M-PER reagent (Pierce) supplemented with protease and phosphatase inhibitors (Roche) and quantified by immunoblot analysis employing antibodies to: cyclin D1, β-catenin, GLUT1, PFK1, PFK2P, mtTFA, NRF1 (Santa Cruz Biotechnology); ATP5A1, COXI, Core II (Invitrogen); GLUT1, TSC1, TSC2 (Millipore); others were from Cell Signaling. Relative intensity reflects the mean of 5–15 individual animals per genotype, 12 paired human tumor and normal adjacent tissues, or ≥3 independent experiments with cultured cells.

Cell proliferation and crypt number

Ki-67 was used as a proliferation marker to quantify dividing cells by blinded-analysis from 5–15 crypt-villus units/segment/mouse.19 Results reflect the mean ± SEM of at least 9 animals in each group. DNA synthesis was quantified by [3H]thymidine incorporation.21 Crypt number was calculated from complete crypts in at least 5 transverse cross sections/intestinal segment/mouse.

Real-time PCR

Total RNA was subjected to one-step RT-PCR using TaqMan® EZ RT-PCR Core Reagents and specific primer/probes for TaqMan® Gene Expression Assays in an ABI 7000 (Applied Biosystems). Relative expression was calculated using the 2−ΔΔCT method and GAPDH or β-actin as reference.

Lactate production and glucose uptake

Lactate production and glucose uptake using 3H-deoxyglucose (50 µCi/mL), were quantified in isolated mouse intestinal mucosae. In cells, lactate production was quantified using a lactate measurement kit (Trinity Biotech) while glucose uptake was quantified employing 2-NBDG.

Mitochondrial function

Mitochondrial reductase activity was quantified by MTT analysis. Oxygen consumption was measured using the Oxygen Biosensor System (BD Bioscience). Mitochondria-specific ATP production was quantified using an ATP determination kit (Invitrogen). ROS production was quantified by Image-iT® LIVE Reactive Oxygen Species Kit (Invitrogen).

Microarray analyses

Microarray analyses, using the Affymetrix Mouse 430 2.0 3’-IVT platform, were performed on RNA extracted from intestine of Gucy2c+/+ and Gucy2c−/− littermates (n=4 each).

Statistical analyses

Cell proliferation quantified by Ki-67 IHC was analyzed by linear mixed effects models while tumor incidence was analyzed by Pearson's chi-square test.18 Measurements at single time points were analyzed by ANOVA or, if appropriate, by t test unless otherwise specified. Unless otherwise indicated, results represent means ± SEM from at least 3 animals or 3 experiments performed in triplicate.


GUCY2C signaling coordinates proliferation and metabolism in intestinal epithelial cells

Elimination of GUCY2C signaling in mice (Gucy2c−/−) expanded the size (Figure 1A) and number (Figure 1B) of crypts, associated with an increase in proteins promoting the cell cycle transition, including cyclin D1, cyclin-dependent kinase (CDK4), phosphorylated Rb (pRb), and β-catenin, while decreasing the cyclin-dependent kinase inhibitor p27 (Figures 1C). Expansion of the proliferating compartment was coupled with epithelial bioenergetic reprogramming, with increased glycolytic metabolism along the crypt-surface axis, resembling the tumor metabolic phenotype (Figures 2A).4, 22 Conversely, the mitochondrial genome and proteins of epithelial cells were decreased (Figures 2B). Further, staining of mitochondrial protein (Figure 2C) and direct visualization of mitochondria by electron microscopy (Figure 2D) revealed disruption of the crypt-surface gradient of mitochondria normally characterizing compartmentalization of proliferation and differentiation along that axis,23 reflecting a decrease of mitochondria, which exhibited abnormal structure, in the differentiated villus compartment (Figure 2D).24 Deregulation of the metabolic machinery increased glucose uptake and aerobic glycolysis reflected by increased lactate accumulation (Figure 2E). Further, mitochondrial oxygen consumption and dehydrogenase activity were reduced (Figure 2F). Proliferative and metabolic programming in the absence of GUCY2C signaling in mice recapitulated the phenotype in human colorectal tumors. Indeed, reduced guanylin in tumors (Figure S1A) was associated with increased cyclin D1 and decreased p27 regulating the G1/S transition (Figure S1B); increased GLUT1 and HKII regulating glycolysis (Figure S1C), and diminished electron transport complexes IV and V reflecting reduced mitochondrial oxidative phosphorylation (Figure S1D). Thus, beyond developmental programs controlling proliferation and differentiation important in spatiotemporal patterning, GUCY2C coordinates metabolic circuits along the crypt-surface axis.18 Moreover, disruption of GUCY2C expression, which mimics loss of guanylin and uroguanylin during transformation, induces proliferative and metabolic deregulation characterizing survival mechanisms in cancer.1, 2, 4, 19, 22

Figure 1
GUCY2C regulates intestinal epithelial cell proliferation
Figure 2
GUCY2C coordinates metabolism in intestinal epithelial cells

Restoring GUCY2C signaling reverses neoplastic proliferative and metabolic phenotypes

Activation of GUCY2C signaling in human colon cancer cells by the heat-stable enterotoxin, ST, or its downstream effector, cGMP, reduced expression of cyclin D1 and pRb and increased p27 which, together, arrest the cell cycle (Figure 3A). Indeed, GUCY2C signaling delayed cell cycle progression (Figure 3B), and reduced DNA synthesis (Figure 3C) and colony formation (Figure 3D). Moreover, oral administration of the downstream effector of GUCY2C, cGMP, but not its inactive metabolite, GMP, restored crypt proliferative homeostasis in Gucy2c−/− mice (Figure 3E), with a decrease in proliferating (Ki67-positive) cells in the crypt and absence of proliferating cells in the villus (Figure 3F), mimicking the effects of GUCY2C activation in human colon cancer cells.

Figure 3
GUCY2C opposes proliferation in colon cancer cells and remodels the proliferative compartment in GUCY2C−/− mice

Proliferative restriction was coupled with glycolytic reprogramming, reflected by decreased glucose uptake, lactate production (Figure 4A), and expression of rate-limiting enzymes mediating glycolysis that are typically over-expressed in tumors (Figure 4B).4, 22 ST effects were mediated by the canonical guanylyl cyclase catalytic domain, and GUCY2C constructs lacking that domain (TM) did not regulate proliferation or metabolism (Figure S2). The metabolic gap resulting from reduced glycolysis was bridged by increases in mitochondrial biogenesis. ST increased mtTFA, NRF-1, and PGC1α in a GUCY2C-dependent fashion (Figure S3A), reflected by increases in mitochondrial content, including organelle-specific proteins (Figure S3B) and DNA (Figure S3C), and functional efficiency, including oxygen consumption, dehydrogenase activity, and ATP production (Figure 4C). Increased efficiency in coupling electron transport and ATP production was associated with reduced production of reactive oxygen species (ROS; Figure 4D). This might contribute to the increase in oxidative DNA damage (Figure 4E) and therefore an increase in tumor susceptibility19 due to loss of GUCY2C signaling. Similar to proliferative regulation, oral administration of cGMP reversed tumorigenic metabolism in Gucy2c−/− mice (Figure 4F). Thus, survival pathways reflecting dysregulated GUCY2C and characterizing human colon cancer cells can be dynamically regulated in vitro and in vivo by reconstituting intestinal cGMP signaling.

Figure 4
GUCY2C signaling reverses the tumor metabolic phenotype in human colon cancer cells and GUCY2C−/− mice

GUCY2C regulates AKT signaling in intestinal cells

To identify the mechanism mediating preneoplastic transformation of intestinal epithelia in the absence of GUCY2C signaling, we performed microarray analysis to profile mRNA expression using both KEGG (Kyoto Encyclopedia of Genes and Genomes) and Biocarta pathway database annotations. AKT, a common signaling node regulating proliferation and metabolism, integrates cell survival circuits driving crypt developmental programs and its over-activation characterizes early colorectal tumorigenesis.2530 Microarray profiling revealed that AKT pathways are the most significantly differentially activated in intestine from Gucy2c−/−, compared to Gucy2c+/+, mice (KEGG database, p=1.1 × 10−6; Biocarta database, p=8.5 × 10−4; Figure 5A). Indeed, among 18 AKT-related pathways, 17 are significantly altered (p<0.029) by loss of GUCY2C (Figure 5A2). Eliminating GUCY2C resulted in increased AKT phosphorylation in intestinal cells (Figure 5B) at Thr308 and Ser473 (Figure 5C, pink), both of which are essential for AKT activity, recapitulating the over-activation of AKT in human colorectal cancer. Activation of canonical survival pathways by AKT1 induced by loss of GUCY2C was reflected by increased downstream TSC1/TSC2 degradation following TSC2 phosphorylation, which, in turn, increased mTOR signaling, a key integrator coordinating proliferative and metabolic signals required for cell growth and survival (Figure 5C, green).28, 31 Further, mTOR increased phosphorylation of S6K (Figure 5C, green), activating the translational machinery required for proliferation,31 and FOXO1, a key transcription factor promoting PGC1α function and mitochondrial biogenesis,32, 33 resulting in its nuclear exclusion and degradation (Figure 5C, blue), coordinately rebalancing metabolism favoring glycolysis.26 Conversely, restoring GUCY2C signaling by oral administration of cGMP specifically reduced AKT (Figure 5D, pink), but not MAP kinase (Figure 5D, brown), signaling in Gucy2c−/− mice. Moreover, in human colon cancer cells, GUCY2C signaling reversed oncogenic AKT activation and downstream effector mechanisms sustaining proliferation and metabolic reprogramming, including TSC2, mTOR, and FOXO1 (Figure 5E).

Figure 5
GUCY2C regulates AKT signaling

GUCY2C restricts oncogenic replicative and metabolic circuits through AKT inhibition

To further explore the causality between GUCY2C-mediated replicative and metabolic homeostasis and AKT regulation, we utilized pharmacological inhibition and adenovirus-mediated gene transfer to modulate AKT signaling. AKT can be silenced with SH6 (Figure 6A), which blocks membrane translocation and phosphorylation, or with AKT siRNA (siAKT; Figure 6B–E).2527, 29 Eliminating AKT activity with SH6 (Figure 6A) or siAKT (Figure 6B) mimics GUCY2C signaling and blocks the effects of ST and cGMP, examined by proliferative (CyclinD), glycolytic (HKII) and mitochondrial (COXI) markers. The role of AKT in GUCY2C-mediated proliferative restriction was further confirmed by decreased DNA synthesis (Figure 6C), associated with metabolic rebalancing by increased mitochondrial content (Figure 6D) and a reciprocal reduction in glycolysis (Figure 6E). Conversely, myristoylation directly localizes AKT to membrane sites for phosphorylation, producing constitutive activation (myrAKT; Figure 6B–E).32 MyrAKT mimics elimination of GUCY2C signaling, and blocks the reverting effects of ST and cGMP, promoting expression of cell cycle mediators (Figure 6B, CyclinD), DNA synthesis (Figure 6C) and tumorigenic metabolism, reducing mitochondria protein (Figures 6B, COXI, and D) and enhancing glycolysis (Figure 6B, HKII, and E). Moreover, reducing AKT expression through gene disruption rescued the amplification of AOM-induced tumorigenesis produced by gene-targeted silencing of GUCY2C signaling in both small intestine and colon (Figure 7).

Figure 6
GUCY2C deprives cancer cells of replicative and metabolic survival advantages through AKT inhibition
Figure 7
GUCY2C regulates intestinal tumorigenesis through AKT

GUCY2C regulates AKT in a PTEN-dependent manner

Activation of AKT, in part, reflects the balance between oncogenic PI3K and the tumor suppressor PTEN, which together dynamically regulate phosphatidylinositol-3,4,5-triphosphate (PIP3) available for directing membrane translocation and PDK-1 activation mediating AKT phosphorylation.25, 28 Elimination of GUCY2C in mice reduced PTEN expression and activity by increasing inhibitory phosphorylation (Figure 5C). Conversely, induction of cGMP signaling in human colon cancer cells increased PTEN expression and activity by reducing the ratio of phosphorylated (inactive) to total protein (Figure 8A). Moreover, silencing PTEN with siRNA (siPTEN) mimicked the effects of abolishing GUCY2C expression, and blocked the effects of cGMP on AKT activation and its downstream signaling (Figure 8B) and on key mediators of glycolysis (HKII), mitochondrial biogenesis (COXIV), and proliferation (CyclinD, Figure 8C). Taken together, these data indicate that GUCY2C regulates replicative and metabolic homeostasis in normal intestinal epithelium and tumors by modulating AKT activity, in part, in a PTEN-dependent manner.

Figure 8
GUCY2C regulates AKT in a PTEN dependent manner


There is a common process for transformation in all cells involving the evolution of autonomous growth and survival through deregulation of homeostatic processes underlying proliferation and metabolism.1, 22 This evolution is rooted in the genetic basis of cancer, in which the graded progression of the malignant phenotype reflects accumulation of sequential mutations.34, 35 In turn, this genetic instability reflects self-reinforcing cycles of proliferation uncoupled from normal DNA damage sensing and repair, promoted by metabolic remodeling and disabled apoptosis.1, 2, 4, 22, 34, 35 These amplifying mechanisms produce pervasive corruption of the genome and downstream homeostatic circuits, conferring phenotypic characteristics pathognomonic of the distal end of the transformation continuum including autonomous survival, invasion, metastasis, and resistance to therapy. Beyond this oncogenomic view of cancer, lineage-dependent tumorigenesis suggests that developmental programs imprint tissue-specific mechanisms integrating proto-oncogenes and tumor suppressors in survival circuits, which coordinate fundamental homeostatic pathways.3, 35 Genomic or other pathophysiologic insults which corrupt these lineage-dependent programs, and the resultant deregulation of subordinate survival circuits, may represent the earliest events initiating or promoting the neoplastic continuum and the best opportunity for targeted prevention of cancer.

In that context, the present observations provide an adjunctive taxonomic perspective to colorectal tumorigenesis beyond a genetic disease reflecting sequential mutations in oncogenes and tumor suppressors.34 Indeed, silencing of the intestinal homeostatic receptor GUCY2C, reflecting loss of paracrine hormone ligands,15, 16 promotes tumor initiation by inducing the proto-oncogene AKT which disrupts homeostatic replicative and bioenergetic programming, producing hyperproliferation and metabolic deregulation, both of which promote accumulation of mutations and tumor progression.1, 2, 4, 22 Hyperproliferation reflects the established role of GUCY2C and its ligands in organizing the crypt-surface axis, restricting the size of the crypt compartment, the number of cells proliferating, and the rate of the cell cycle through the G1-S transition.18 Metabolic deregulation extends the function of cGMP in programming mitochondrial biogenesis and oxidative metabolism with a previously unrecognized role in coordinately modulating aerobic glycolysis critical for energy independence and anabolic biosynthesis supporting hyperproliferation.4, 22, 36 Further, hyperproliferation, which expands the propagation of somatic mutations, and metabolic deregulation, which increases production of DNA-damaging ROS, cooperate to amplify genetic instability and promotes tumorigenesis.37, 38

The present observations underscore the evolving critical importance of the AKT signaling axis in tumorigenesis. Amplifications and mutations enhancing PI3K activity characterize tumors originating from a variety of tissues and drive transformation.39, 40 Indeed, RAS mutations producing constitutive activation support tumor initiation and maintenance through activation of AKT signaling.41 Moreover, PTEN is mutated, associated with loss of function, in a broad spectrum of tumors.42 Indeed, PTEN-PI3K/AKT signaling is one of the most frequently altered pathways in colorecal cancer.27 This pathway constitutes a central node integrating mitogenic, pro-oncogenic, and tumor suppressing signals to coordinate programs, including the cell cycle, metabolism, DNA repair, and apoptosis, at the intersection of tissue homeostasis and tumorigenesis.26, 43 The present study suggests a model of colorectal preneoplasia in which pro-oncogenic signaling by the PTEN-PI3K/AKT axis is engaged, in the absence of component mutations, through a lineage-specific mechanism involving silencing of the intestinal gene product GUCY2C by loss of paracrine hormone expression. Targeting GUCY2C with receptor-specific ligands offers a unique approach to prevent or treat colorectal cancer, circumventing upstream oncogenomic alterations, including mutation or gene amplification, of RTKs, KRAS, or PI3K by suppressing AKT and dependent survival circuits critical to tumor cell autonomy, without off-target adverse effects in tissues devoid of GUCY2C expression.

It is worth noting that dysregulated GUCY2C alone does not induce spontaneous transformation, underscoring the significance of the integrity of compensatory apoptotic mechanisms in the context of hyperproliferation, metabolic reprogramming and loss of genomic integrity.18, 19 Rather, loss of GUCY2C signaling collaborates with mutations in key regulatory elements of the Wnt pathway, including APC and β-catenin, which, in part, uncouple apoptotic mechanisms to promote intestinal tumorigenesis.19, 44 Moreover, there may be a cause and effect relationship between silencing of GUCY2C and APC loss of heterozygosity early in transformation.19 These observations suggest a model of lineage-addicted tumorigenesis in colorectal cancer in which disruption of homeostatic cGMP signaling permits the universal tissue-specific inactivation of APC,3, 45 possibly through AKT-mediated inhibition of Chk1 by phosphorylation,26 or enhanced p53 degradation.46 This paradigm in which GUCY2C silencing establishes the tissue-specific context for corruption of APC signaling suggests an appealing model for cancer prevention in which maintenance of cGMP homeostasis through paracrine hormone receptor activation preserves APC function, opposing neoplasia.47

Loss of guanylin and uroguanylin at the earliest stages of premalignancy suggests a lineage-dependent model of intestinal tumorigenesis,3, 1517 initiating as a disease of tissue-specific paracrine hormone insufficiency.48 The resultant silencing of GUCY2C produces maladaptive spatiotemporal amplification of survival circuits and, subsequently, DNA damage and mutations contributing to the genetic basis of colorectal cancer. This unique model of intestinal transformation as a paracrine hormone deficiency has substantial implications for the prevention and treatment of colorectal cancer. Indeed, GUCY2C is over-expressed by intestinal tumors compared to normal adjacent tissues.49, 50 Early loss of hormones and compensatory over-expression of receptors offers a unique therapeutic window preceding the accumulation of mutations corrupting subordinate survival pathways to prevent maladaptive reprogramming and the evolution of cancer through oral GUCY2C hormone replacement therapy.47

Supplementary Material




Grant support

These studies were supported by grants from NIH (CA75123, CA95026) and Targeted Diagnostic and Therapeutics Inc. to SAW, and NIH (CA133950), the Pennsylvania Department of Health and the Prevent Cancer Foundation to GMP. The Pennsylvania Department of Health and NIH specifically disclaim responsibility for any analyses, interpretations or conclusions.


v-akt murine thymoma viral oncogene homolog
adenomatous polyposis coli
cyclic GMP
the forkhead box O transcription factor
guanylyl cyclase C
glucose transporter I
hexokinase II
mammalian target of rapamycin
peroxisome proliferator-activated receptor gamma coactivator 1α
pyruvate kinase
phosphorylated retinoblastoma
RAS homolog enriched in brain
reactive oxygen species
receptor tyrosine kinase
diarrheagenic bacterial heat-stable enterotoxin
tuberous sclerosis complex


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

List of Contributions

Study concept and design:

Jieru Egeria Lin, Peng Li, Adam Eugene Snook, Stephanie Schulz, Abhijit Dasgupta, Terry Marie Hyslop, Giovanni Mario Pitari, Scott Arthur Waldman

Acquisition of data:

Jieru Egeria Lin, Peng Li, Stephanie Schulz, Abhijit Dasgupta

Analysis and interpretation of data:

Jieru Egeria Lin, Peng Li, Abhijit Dasgupta, Terry Marie Hyslop, Scott Arthur Waldman

Drafting of the manuscript:

Jieru Egeria Lin, Peng Li, Adam Eugene Snook, Stephanie Schulz, Abhijit Dasgupta, Terry Marie Hyslop, Giovanni Mario Pitari, Scott Arthur Waldman

Critical revision of the manuscript for important intellectual content:

Jieru Egeria Lin, Scott Arthur Waldman

Statistical analysis:

Jieru Egeria Lin, Abhijit Dasgupta, Terry Marie Hyslop


Giovanni Mario Pitari, Scott Arthur Waldman

Technical or material support:

Adam Eugene Snook, Stephanie Schulz, Ahmara Vivian Gibbons, Glen Marszlowicz

Study supervision:

Stephanie Schulz, Giovanni Mario Pitari, Scott Arthur Waldman



SAW is a paid consultant to Merck, and the Chair (uncompensated) of the Scientific Advisory Board of Targeted Diagnostics and Therapeutics, Inc., which provided research funding that, in part, supported this work and which has a license to commercialize inventions related to this work. GMP receives research salary support from Merck. He is an inventor on patents which include information contained in this manuscript. All the other authors have no conflict of interest to disclose.


1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. [PubMed]
2. Massague J. G1 cell-cycle control and cancer. Nature. 2004;432:298–306. [PubMed]
3. Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer. 2006;6:593–602. [PubMed]
4. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008;13:472–482. [PubMed]
5. Yang WC, Mathew J, Velcich A, Edelmann W, Kucherlapati R, Lipkin M, Yang K, Augenlicht LH. Targeted inactivation of the p21(WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res. 2001;61:565–569. [PubMed]
6. Sakatani T, Kaneda A, Iacobuzio-Donahue CA, Carter MG, de Boom Witzel S, Okano H, Ko MS, Ohlsson R, Longo DL, Feinberg AP. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science. 2005;307:1976–1978. [PubMed]
7. Garber K. Energy deregulation: licensing tumors to grow. Science. 2006;312:1158–1159. [PubMed]
8. Hamra FK, Forte LR, Eber SL, Pidhorodeckyj NV, Krause WJ, Freeman RH, Chin DT, Tompkins JA, Fok KF, Smith CE, et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci U S A. 1993;90:10464–10468. [PubMed]
9. Schulz S, Green CK, Yuen PS, Garbers DL. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell. 1990;63:941–948. [PubMed]
10. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375–414. [PubMed]
11. Currie MG, Fok KF, Kato J, Moore RJ, Hamra FK, Duffin KL, Smith CE. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci U S A. 1992;89:947–951. [PubMed]
12. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, Waldman SA. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum Pathol. 2005;36:170–179. [PubMed]
13. Carrithers SL, Barber MT, Biswas S, Parkinson SJ, Park PK, Goldstein SD, Waldman SA. Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. Proc Natl Acad Sci U S A. 1996;93:14827–14832. [PubMed]
14. Cohen MB, Witte DP, Hawkins JA, Currie MG. Immunohistochemical localization of guanylin in the rat small intestine and colon. Biochem Biophys Res Commun. 1995;209:803–808. [PubMed]
15. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW. Gene expression profiles in normal and cancer cells. Science. 1997;276:1268–1272. [PubMed]
16. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 2001;61:3124–3130. [PubMed]
17. Glebov OK, Rodriguez LM, Soballe P, DeNobile J, Cliatt J, Nakahara K, Kirsch IR. Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa. Cancer Epidemiol Biomarkers Prev. 2006;15:2253–2262. [PubMed]
18. Li P, Lin JE, Chervoneva I, Schulz S, Waldman SA, Pitari GM. Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. Am J Pathol. 2007;171:1847–1858. [PubMed]
19. Li P, Schulz S, Bombonati A, Palazzo JP, Hyslop TM, Xu Y, Baran AA, Siracusa LD, Pitari GM, Waldman SA. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology. 2007;133:599–607. [PubMed]
20. Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008;100:950–961. [PMC free article] [PubMed]
21. Pitari GM, Di Guglielmo MD, Park J, Schulz S, Waldman SA. Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. Proc Natl Acad Sci U S A. 2001;98:7846–7851. [PubMed]
22. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008;18:54–61. [PMC free article] [PubMed]
23. Madsen KL, Brockway PD, Johnson LR, Hardin JA, Gall DG. Role of ornithine decarboxylase in enterocyte mitochondrial function and integrity. Am J Physiol. 1996;270:G789–G797. [PubMed]
24. Frey TG, Mannella CA. The internal structure of mitochondria. Trends Biochem Sci. 2000;25:319–324. [PubMed]
25. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–619. [PubMed]
26. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129:1261–1274. [PMC free article] [PubMed]
27. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–1113. [PubMed]
28. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6:184–192. [PubMed]
29. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892–3899. [PubMed]
30. Sheng H, Shao J, Townsend CM, Jr, Evers BM. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut. 2003;52:1472–1478. [PMC free article] [PubMed]
31. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484. [PubMed]
32. Li X, Monks B, Ge Q, Birnbaum MJ. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1alpha transcription coactivator. Nature. 2007;447:1012–1016. [PubMed]
33. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC, Spiegelman BM. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 1999;98:115–124. [PubMed]
34. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789–799. [PubMed]
35. Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002;297:63–64. [PubMed]
36. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, Carruba MO. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 2003;299:896–899. [PubMed]
37. Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/− compound mutant mice. Nat Genet. 2003;35:323–330. [PubMed]
38. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature. 1999;401:297–300. [PubMed]
39. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. [PubMed]
40. Samuels Y, Diaz LA, Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005;7:561–573. [PubMed]
41. Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumour maintenance is mediated by eNOS. Nature. 2008;452:646–649. [PMC free article] [PubMed]
42. Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22:183–198. [PubMed]
43. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–262. [PubMed]
44. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A. 1996;93:7950–7954. [PubMed]
45. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer. 2004;4:769–780. [PubMed]
46. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell. 2007;12:303–312. [PubMed]
47. Shailubhai K, Yu HH, Karunanandaa K, Wang JY, Eber SL, Wang Y, Joo NS, Kim HD, Miedema BW, Abbas SZ, Boddupalli SS, Currie MG, Forte LR. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res. 2000;60:5151–5157. [PubMed]
48. Pitari GM, Li P, Lin JE, Zuzga D, Gibbons AV, Snook AE, Schulz S, Waldman SA. The paracrine hormone hypothesis of colorectal cancer. Clin Pharmacol Ther. 2007;82:441–447. [PubMed]
49. Schulz S, Hyslop T, Haaf J, Bonaccorso C, Nielsen K, Witek ME, Birbe R, Palazzo J, Weinberg D, Waldman SA. A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin Cancer Res. 2006;12:4545–4552. [PubMed]
50. Witek ME, Nielsen K, Walters R, Hyslop T, Palazzo J, Schulz S, Waldman SA. The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin Cancer Res. 2005;11:8549–8556. [PubMed]